Conservative as it should be for a 12 month target.
Long term one needs to calculate the value of 15%+ royalties earned in a $3+B market without a viable competing drug for 10 years.
i.e. $450,000+ per annum.
Hell, be conservative and assume all the milestone payments only cover off all of the costs of commercialization and ongoing ops.
$4.5B plus in royalties.
Big numbers.
$2, page-27
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.0¢ |
Change
0.020(3.92%) |
Mkt cap ! $291.6M | |||
| Open | High | Low | Value | Volume |
| 51.0¢ | 53.8¢ | 51.0¢ | $782.0K | 1.490M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6408 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 35657 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |